Firefly Neuroscience

Company Overview

Snapshot

Founded in January 2006 by Amir Geva, Firefly Neuroscience operates with 11–50 employees. The company has raised $82.59M across 11 funding rounds from 8 investors. Firefly Neuroscience became public on NASDAQ in November 2021.

Business overview

Firefly Neuroscience develops Brain Network Analytics (BNA™) technology, an AI and advanced signal processing platform that provides objective assessments of brain function. This technology records and compares brain activity to an FDA-cleared, age-matched normative database, enabling clinicians and patients to make informed decisions for therapy and disease management, and to track changes over time. The company aims to reduce subjectivity in managing mental illnesses and cognitive disorders, serving the Health Tech & Life Sciences sector, particularly in digital healthcare and medical decision support.

Strategic signal

In May 2025, Firefly Neuroscience acquired Evoke Neuroscience, Inc., significantly expanding its database, IP portfolio, and commercial footprint. This acquisition signals a strategic move to consolidate its market position and enhance its offerings in brain health assessment, indicating a strong focus on growth through inorganic expansion and intellectual property development.

Company Intelligence Q&A

When did Firefly Neuroscience go public?

Firefly Neuroscience went public on NASDAQ in November 2021.

What was a significant recent corporate development for Firefly Neuroscience?

In May 2025, Firefly Neuroscience acquired Evoke Neuroscience, Inc., which expanded its database, IP portfolio, and commercial footprint.

Has Firefly Neuroscience recently engaged in any strategic partnerships?

In September 2025, Firefly Neuroscience partnered with HealingMaps to offer cognitive electrophysiology analytics to over 2,500 ketamine, psilocybin, and TMS clinics across North America.

What is the status of Firefly Neuroscience's AI-driven technology development?

In March 2026, Firefly Neuroscience progressed toward the development and commercial launch of its foundation model of the human brain, powered by NVIDIA GPU acceleration.

Did Firefly Neuroscience announce any new biomarker discoveries?

In March 2026, Firefly Neuroscience announced the discovery of new brain wave biomarkers for the differential diagnosis of ADHD.